Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Stopped A phase III trial of the investigational agent failed to pass futility boundaries at interim analysis
Conditions
- Head and Neck Squamous Cell Carcinoma
- Hypopharyngeal Squamous Cell Carcinoma
- Laryngeal Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage III Hypopharyngeal Carcinoma AJCC v8
- Stage III Laryngeal Cancer AJCC v8
- Stage III Lip and Oral Cavity Cancer AJCC v8
- Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Stage IV Hypopharyngeal Carcinoma AJCC v8
- Stage IV Laryngeal Cancer AJCC v8
- Stage IV Lip and Oral Cavity Cancer AJCC v8
- Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
- PROCEDURE: Biospecimen Collection
- DRUG: Carboplatin
- PROCEDURE: Chest Radiography
- DRUG: Cisplatin
- PROCEDURE: Computed Tomography
- RADIATION: Image Guided Radiation Therapy
- RADIATION: Intensity-Modulated Radiation Therapy
- PROCEDURE: Magnetic Resonance Imaging
- PROCEDURE: Positron Emission Tomography
- DRUG: Xevinapant
Sponsor
ECOG-ACRIN Cancer Research Group
Collaborators